A study on mutations in Von-Hippel-Lindau (VHL) syndrome families revealed that: What does this mean?• In families that meet clinical criteria for VHL without a detectable VHL pathogenic variant whole genome sequencing may be considered for further analysis To learn more, read the full article at:https://pubmed.ncbi.nlm.nih.gov/33675279/ Reference: Vocke CD, et al. Hum Mutat. 2021; 42(5):520-529. …
Permanent link to this article: https://inheritedcancer.net/post120424/
A recent study in carriers with Von-Hippel-Lindau Syndrome, an inherited condition that causes tumors and cysts to grow in certain areas of the body, found:▪️ Nearly 100% of carriers show some signs of this condition by age 65▪️ Demonstrates that this condition is highly penetrant Read the full article to learn more at:https://pubmed.ncbi.nlm.nih.gov/34916234/ Reference: Zhang …
Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-december-2024-vhl-syndrome-characteristics/
Lynch Syndrome Carriers with Advanced Uterine Cancer: Treatment with PembrolizumabWomen with Lynch Syndrome are at high risk for uterine cancer. The type of uterine cancer they develop has the tumorcharacteristic of being ‘MSI-H’. A new study indicated treatment with pembrolizumab (Keytruda) resulted in benefit inpatients with MSI-H advanced uterine cancer. Von Hippel-Lindau Patients: Treatment of …
Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-inherited-cancer-treatment-updates/
Jan 21
Belzutifan demonstrated clinical efficacy in patients with renal cell carcinoma who have Von Hippel-Lindau Disease. Learn more by reading the full The New England Journal of Medicine article at 👇https://www.nejm.org/doi/full/10.1056/NEJMoa2103425Reference: Jonasch, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. PMID: 34818478.
Permanent link to this article: https://inheritedcancer.net/post12122/
On August 13th, the FDA approved the use of belzutifan (Welireg) for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery. For more information, check out The ASCO Post article at 👇https://ascopost.com/news/august-2021/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease/?utm_source=TAP-EN-081321&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769
Permanent link to this article: https://inheritedcancer.net/post121021/
For additional information, please visit: https://www.onclive.com/view/fda-grants-breakthrough-status-to-mk-6482-for-select-vhl-disease-associated-rcc Also check out the abstract presented at the 2020 ASCO meeting: https://meetinglibrary.asco.org/record/185945/abstract
Permanent link to this article: https://inheritedcancer.net/post92220/
There continue to be ongoing advances in treatment studies among those with inherited cancer gene mutations, which are rapidly being followed by FDA approval for specific cancer treatments. Select studies and advances are summarized below: Von-Hippel Lindau (VHL) Disease: Among patients with VHL-associated clear cell renal cell carcinoma (RCC), a recent study suggested potential benefit …
Permanent link to this article: https://inheritedcancer.net/9nls2020/
Additional exciting advances include the results of a new drug (pazopanib) to treat an inherited cancer condition called von Hippel-Lindau Disease (VHL), in which patients are predisposed to kidney cancers, pancreatic tumors, and hemangioblastomas (i.e., tumors involving the blood vessels). Study results showed that among 31 patients with VHL, overall response rate with the drug …
Permanent link to this article: https://inheritedcancer.net/8nlw2019/
